Sera Prognostics, Inc. (NASDAQ:SERA – Get Free Report)’s share price was up 0.4% on Friday . The company traded as high as $7.35 and last traded at $7.25. Approximately 49,759 shares were traded during trading, a decline of 75% from the average daily volume of 196,666 shares. The stock had previously closed at $7.22.
Sera Prognostics Price Performance
The firm has a market capitalization of $241.93 million, a price-to-earnings ratio of -6.78 and a beta of 1.03. The firm has a 50 day moving average price of $7.12 and a 200-day moving average price of $8.33.
Sera Prognostics (NASDAQ:SERA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 46.71%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.08 million. During the same period in the prior year, the business earned ($0.34) EPS. Equities research analysts predict that Sera Prognostics, Inc. will post -0.95 earnings per share for the current year.
Insider Buying and Selling
Institutional Trading of Sera Prognostics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sanders Morris Harris LLC acquired a new position in shares of Sera Prognostics in the 1st quarter valued at $174,000. StepStone Group LP acquired a new position in Sera Prognostics in the fourth quarter valued at $61,000. The Manufacturers Life Insurance Company acquired a new position in Sera Prognostics in the second quarter valued at $68,000. Renaissance Technologies LLC purchased a new position in shares of Sera Prognostics during the second quarter worth about $162,000. Finally, American Century Companies Inc. increased its position in shares of Sera Prognostics by 12.7% during the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock worth $152,000 after purchasing an additional 2,891 shares in the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.
Sera Prognostics Company Profile
Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.
Featured Articles
- Five stocks we like better than Sera Prognostics
- What is a SEC Filing?
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- There Are Different Types of Stock To Invest In
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- When to Sell a Stock for Profit or Loss
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.